Jay Pepose, MD
Ophthalmology · Chesterfield, MONPI 1134111446
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $460,918 of the $515,863 with a category attached, or 89.3%. Oyster Point Pharma, Inc. accounts for 81.6% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $426,808, 9.9 times the $43,226 reported in 2019. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $1791.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$421K
- Sun Pharmaceutical Industries Inc.$19K
- Kala Pharmaceuticals, Inc.$15K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$14K
- Bausch & Lomb Americas Inc.$14K
- Shire North American Group Inc$7K
- plus $26K from 22 others
Across 4 payments — averaging $4891.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$9K
- Bausch & Lomb Americas Inc.$8K
- Bausch Health US, LLC$3K
What the payments were for
- Consulting fees$460,91889%
- Speaking & faculty fees$30,6766%
- Travel & lodging$15,9373%
- Food & beverage$8,3132%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 79 | $420,756 |
| Sun Pharmaceutical Industries Inc. | 36 | $18,694 |
| Kala Pharmaceuticals, Inc. | 24 | $14,909 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $14,335 |
| Bausch & Lomb Americas Inc. | 28 | $14,090 |
| Shire North American Group Inc | 7 | $7,023 |
| GSK | 1 | $5,850 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $4,352 |
| Genentech USA, Inc. | 4 | $3,554 |
| Dompe US, Inc. | 5 | $3,188 |
| Novartis | 4 | $2,525 |
| Tearlab Corp | 4 | $2,175 |
| Apellis Pharmaceuticals, Inc. | 1 | $2,033 |
| Alcon | 22 | $797 |
| Thea Pharma Inc. | 4 | $391 |
| AbbVie(2 entities) | 14 | $263 |
| Carl Zeiss Meditec, Inc. | 3 | $236 |
| Harrow Eye, LLC | 2 | $174 |
| Biotissue Holdings Inc. | 5 | $131 |
| Glaukos Corporation | 3 | $105 |
| Rxsight Inc | 3 | $79 |
| Tarsus Pharmaceuticals, Inc. | 1 | $56 |
| Sight Sciences, Inc. | 2 | $51 |
| Rayner Intraocular Lenses Limited | 2 | $32 |
| Optos, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Lensar, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ryzumvi$419,144
- CEQUA$15,046
- Tecnis IOL$9,502
- ENVISTA$8,952
- SHINGRIX$5,850
- LOTEMAX SM$4,767
- INVELTYS$4,293
- Tecnis Simplicity$4,050
- Lucentis$3,554
- Oxervate$3,129
- BROMSITE$3,125
- XIIDRA$2,956
- MIEBO$2,206
- TearLab Osmolarity System$2,124
- Syfovre$2,033
- STELLARIS$600
- IYUZEH$309
- enVista MX60 IOL$237
- VisuMax$123
- ARTEVO 800$123
How this compares
$515,863 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 44 | $654 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Chesterfield
- Nancy HolekampChesterfield$768K
- Paul TesserChesterfield$29K
- Mujtaba QaziChesterfield$15K
- Ibrahim Sayed-AhmedChesterfield$9K
- Steven SilversteinKansas City$872K
- Ranjan MalhotraSaint Louis$809K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
- Joseph TauberKansas City$174K
- Jella AnColumbia$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.